Shanghai Universal Biotech Co

Shanghai Universal Biotech Co EBIT Margin

The EBIT Margin (Operating Margin) of Shanghai Universal Biotech Co (301166.SZ) as of Oct 20, 2026 is -3.87 %. In the previous year, EBIT Margin (Operating Margin) was -2.28 % — a change of 69.48% (lower).

EBIT Margin

-3.87 %

YoY

69.48%

Last updated:

EBIT Margin (Operating Margin) of Shanghai Universal Biotech Co is 2025 -3.87 % . EBIT Margin (Operating Margin) of Shanghai Universal Biotech Co was 2024 -2.28 % . It decreases by 69.48% lower compared to the previous year.

Shanghai Universal Biotech Co's operating (EBIT) margin stands at -3.9%, down from 12.4% several years earlier.

The Shanghai Universal Biotech Co EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2018
8.49 CNY
Jan 1, 2019
10.16 CNY
Jan 1, 2020
11.32 CNY
Jan 1, 2021
12.44 CNY
Jan 1, 2022
8.79 CNY
Jan 1, 2023
1.25 CNY
Jan 1, 2024
-2.28 CNY
Jan 1, 2025
-3.87 CNY
The Shanghai Universal Biotech Co EBIT Margin history
YEAREBIT MarginYoY
-3.87 %+69.48%
-2.28 %-282.40%
1.25 %-85.75%
8.79 %-29.38%
12.44 %+9.90%
11.32 %+11.46%
10.16 %+19.62%
8.49 %+37.89%
6.16 %+75,859.72%
0.01 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Shanghai Universal Biotech Co Stock analysis

What does Shanghai Universal Biotech Co do? Shanghai Universal Biotech Co., Ltd. generates revenue through the provision of life science research services, including the supply of third-party brand life science instruments and consumables, alongside its own independent brand products. The company's life science reagents, such as immunological reagents based on antibodies and antibody-related reagents, molecular biology reagents, cell biology reagents, and biochemical reagents, are primarily sourced from third-party brands with supplementary independent brand offerings. Clients purchasing these products include research institutions and laboratories requiring comprehensive technical services like experimental services and technical support. The company focuses on life science instruments and consumables, covering detection, analysis, and sample preparation, while its comprehensive technical services support the operational needs of its clients. The business model emphasizes third-party brand products as the main supply, with independent brand products serving as a supplement. This approach allows Shanghai Universal Biotech to offer a diverse range of life science reagents and instruments without the need for extensive in-house manufacturing. The company's client base primarily consists of entities within the life science research sector seeking reliable reagents, instruments, and technical support to advance their scientific work. By leveraging third-party brands for core products and developing its own independent brand for supplementary offerings, the company optimizes its product portfolio to meet market demands effectively. Shanghai Universal Biotech's revenue streams are derived from the sale of life science reagents, instruments, and consumables, alongside comprehensive technical services. The life science reagents category includes immunological reagents, molecular biology reagents, cell biology reagents, and biochemical reagents, all of which are supplied through a mix of third-party and independent brands. Instruments and consumables focus on detection, analysis, and sample preparation, catering to the technical needs of research institutions. The comprehensive technical services, such as experimental services and technical support, further enhance the value proposition for clients requiring end-to-end solutions in life science research. Shanghai Universal Biotech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Shanghai Universal Biotech Co stock

EBIT Margin (Operating Margin) of Shanghai Universal Biotech Co is -3.87 % in 2025.

EBIT Margin (Operating Margin) of Shanghai Universal Biotech Co changed from -2.28 % to -3.87 %, representing a 69.48% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Shanghai Universal Biotech Co since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Shanghai Universal Biotech Co with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Shanghai Universal Biotech Co

All Key Metrics — Shanghai Universal Biotech Co